# Carbon Monoxide Toxicity

Carbon monoxide toxicity requires exposure-based diagnosis, prompt oxygenation, and assessment for occult neurologic and cardiac injury. Carboxyhemoglobin alone does not define severity or disposition; serial clinical assessment and targeted cardiac evaluation identify patients at risk for acute complications and delayed sequelae.

**Clinical question:** How should clinicians diagnose, risk-stratify, treat, and follow patients with suspected acute carbon monoxide toxicity?

Updated: 2026-08-21T00:03:47.082472Z

## What matters in practice
- Treat suspected carbon monoxide exposure immediately with oxygen; do not wait for confirmatory testing when clinical suspicion is high. CO impairs oxygen delivery and mitochondrial respiration despite a potentially normal PaO2. [7][13]
- Use co-oximetry to measure carboxyhemoglobin, but do not use a single level as the sole determinant of severity, disposition, or risk of delayed sequelae. [7][10]
- Obtain ECG and cardiac biomarkers in suspected acute carbon monoxide poisoning; myocardial injury can be clinically silent and is associated with approximately threefold greater long-term mortality. [7]
- ST-elevation with a concordant regional wall-motion abnormality warrants urgent coronary angiography evaluation; coronary imaging is not required routinely for all carbon monoxide-related myocardial injury. [7]
- Patients with myocardial injury merit structured cardiac reassessment at 2–4 weeks and 6 months; delayed heart failure risk may persist beyond 2 years. [7][11]
- Prevent recurrence through carbon monoxide alarms near sleeping areas, annual fuel-burning appliance servicing, and outdoor generator placement more than 20 feet from windows, doors, and vents. [15]

## Stabilize first and treat on clinical suspicion

Airway, ventilation, circulation, and removal from exposure take precedence over laboratory confirmation.

Carbon monoxide toxicity is an exposure-driven diagnosis. Immediately remove the patient from the source, administer oxygen, and provide standard resuscitation for hypoxemia, hypotension, dysrhythmia, seizure, or cardiac arrest. Carbon monoxide decreases effective oxygen delivery through high-affinity hemoglobin binding and also inhibits mitochondrial respiration; therefore, tissue hypoxia may be severe despite a normal PaO2. [7][9][13]

In patients with altered mental status, syncope, seizure, persistent respiratory compromise, shock, dysrhythmia, or cardiac arrest, pursue critical care stabilization while gathering collateral exposure history. AHA poisoning guidance emphasizes that supportive care, including airway management, breathing support, hemodynamic resuscitation, and correction of metabolic derangements, should not be delayed while identifying a toxicant. [4]
- Suspect exposure with multiple simultaneous patients, enclosed-space combustion, vehicle or generator exhaust, charcoal burning, furnace or appliance malfunction, fire smoke exposure, or unexplained flu-like or neurocognitive symptoms. [15]
- Pulse oximetry is not sufficient to exclude poisoning because it does not distinguish oxyhemoglobin from carboxyhemoglobin; obtain blood co-oximetry when available. [16]
- In smoke inhalation with severe metabolic acidosis, elevated lactate, hypotension, or altered mental status, consider concomitant cyanide poisoning. AHA guidance favors immediate hydroxocobalamin when cyanide is suspected rather than waiting for confirmation. [4]

## Confirm exposure and identify end-organ injury

Carboxyhemoglobin confirms exposure but incompletely reflects clinical severity after oxygen or delayed presentation.

Order co-oximetry for carboxyhemoglobin (COHb) measurement in blood and document the interval from removal from exposure and the oxygen therapy already received. The risk of neurologic sequelae correlates poorly with COHb concentration, and clinical severity must be assessed from exposure history, neurologic findings, cardiopulmonary status, acid-base status, and evidence of organ injury. [10]

Cardiac injury is common enough to warrant systematic initial screening. A contemporary cardiovascular review recommends ECG, troponin I, BNP or NT-proBNP, and transthoracic echocardiography or focused cardiac ultrasound in patients with carbon monoxide poisoning. [7] In a referral cohort with moderate-to-severe poisoning, ischemic ECG changes occurred in 30%, biomarkers were elevated in 35%, and myocardial injury by ECG or biomarkers occurred in 37%. [9]

Repeat troponin testing over 6–12 hours after the initial measurement is reasonable when myocardial injury is suspected or the first result is nondiagnostic. In one cohort summarized in the review, troponin elevation peaked at 11 hours and normalized at a median of 65 hours. [7]

*Initial diagnostic priorities in suspected acute carbon monoxide toxicity. [7][9][10]*

| Domain | Test or assessment | Actionable interpretation |
| --- | --- | --- |
| Exposure | History, source investigation, co-oximetry COHb | A compatible exposure plus symptoms warrants treatment even if COHb is low after oxygen or delayed testing. [7][10] |
| Cardiac | 12-lead ECG and serial troponin I; BNP/NT-proBNP when available | Ischemic changes, dysrhythmia, QT prolongation, or biomarker elevation identify possible myocardial injury and should prompt monitoring and cardiac imaging. [7][9] |
| Structural cardiac injury | Bedside focused cardiac ultrasound or transthoracic echocardiography | Assess global dysfunction, takotsubo pattern, regional wall-motion abnormality, intracardiac thrombus, and shock physiology. [7] |
| Coronary evaluation | Urgent invasive angiography for STEMI-pattern ECG with concordant regional wall-motion abnormality; selective coronary CTA otherwise | Do not routinely image coronary arteries solely because CO-related myocardial injury is present. [7] |
| Neurologic | Serial mental status and cognitive examination | Neurologic, psychological, vestibular, and motor sequelae occur in an estimated 25%–50% of survivors of severe poisoning. [7][10] |

## Oxygen therapy and hyperbaric referral

Supplemental oxygen is the immediate antidotal intervention; hyperbaric oxygen decisions remain individualized.

Normal-pressure oxygen and hyperbaric oxygen are the currently available interventions that reduce carbon monoxide body burden. [10] Hyperbaric oxygen is logistically limited: only approximately 6% of U.S. hospitals have hyperbaric chambers. [10]

The supplied evidence does not establish a universally accepted COHb threshold or a single evidence-based hyperbaric oxygen selection rule. A cardiovascular review states that trials evaluating hyperbaric oxygen specifically for prevention or treatment of carbon monoxide-induced myocardial injury do not exist, but advises hyperbaric oxygen for patients with cardiac injury because of their neurologic risk. [7] An earlier regional hyperbaric center used altered consciousness, seizure, focal neurologic deficit, ischemic chest pain, ECG changes, new dysrhythmia, hypotension, or high COHb with selected clinical risk factors as treatment indications; this was a center protocol, not a contemporary universal standard. [9]

Consult a poison center or medical toxicologist early for significant exposure, persistent neurologic symptoms, pregnancy, myocardial injury, dysrhythmia, hemodynamic instability, or consideration of hyperbaric oxygen. U.S. poison centers provide case-specific treatment guidance through 1-800-222-1222. [4]
- Do not defer oxygenation or resuscitation while arranging hyperbaric consultation. [4]
- Treat acute coronary syndromes according to standard cardiology pathways when indicated; CO exposure can cause myocardial ischemia or infarction with or without obstructive coronary disease. [7][9]
- If CO-related LV dysfunction causes shock, use strict hemodynamic monitoring and manage according to the observed phenotype; specific cardiovascular drug therapy for CO-induced dysfunction has not been established. [7]

## Recognize and monitor carbon monoxide-related myocardial injury

Transient biomarker or echocardiographic normalization does not eliminate long-term cardiovascular concern.

CO-related myocardial injury can reflect tissue hypoxia, direct myocyte toxicity, mitochondrial inhibition, oxidative-inflammatory injury, vasospasm, thrombosis, or dysrhythmogenic effects. [7] In patients with elevated troponin and no known cardiovascular disease, cardiac magnetic resonance demonstrated late gadolinium enhancement in 69.2%, commonly with a midwall pattern; at approximately 4 months, late gadolinium enhancement was unchanged in 67.6% and worsened in 5.4%. [7]

Myocardial injury has prognostic importance. In long-term follow-up summarized in the JACC review, mortality among CO-poisoned patients with myocardial injury was approximately threefold higher than among those without injury. [7] A 2025 cohort also found that higher initial troponin and need for intubation were associated with neurologic sequelae at 1 month, reinforcing the importance of cardiovascular compromise as a risk marker. [10]

Serial echocardiography is appropriate when initial imaging identifies dysfunction. Global dysfunction often resolves rapidly, whereas a takotsubo pattern may resolve less quickly and has reported thromboembolic complications. [7] Consider cardiac MRI in patients with elevated troponin even when echocardiography is unrevealing, recognizing that this is an expert-review recommendation rather than a U.S. society guideline. [7]

## Plan follow-up for delayed neurologic and cardiac sequelae

Disposition should reflect clinical course and end-organ injury rather than COHb alone.

The supplied literature supports prolonged observation or admission for patients with persistent neurologic findings, syncope, seizures, cardiopulmonary instability, dysrhythmia, ECG abnormalities, elevated cardiac biomarkers, or ventricular dysfunction. [4][7][9] COHb concentration should not independently determine discharge because it can fall after removal from exposure and oxygen treatment and correlates poorly with delayed neurologic risk. [10]

For patients with CO-related myocardial injury, expert recommendations advise cardiac reassessment at 2–4 weeks and 6 months, with ECG, echocardiography, ambulatory rhythm assessment if arrhythmias occurred, and consideration of cardiac MRI based on acute findings. [7] A population-based study cited by the review found heart failure risk peaked in the first month and persisted in some patients for more than 2 years. [7][11]

At follow-up, actively elicit new or delayed cognitive, mood, vestibular, gait, or motor symptoms. Severe CO poisoning survivors have an estimated 25%–50% risk of neurologic injury, and delayed neurocognitive morbidity can occur despite apparent early recovery. [7][10]
- Provide explicit return precautions for recurrent confusion, syncope, chest pain, dyspnea, palpitations, exertional intolerance, or new focal neurologic symptoms. [7]
- If exposure was intentional, arrange suicide-risk assessment and psychiatric follow-up as part of disposition planning; the supplied sources identify intentional exposure as a common mechanism in severe clinical cohorts. [9]
- Coordinate public health, fire department, utility, landlord, or occupational safety involvement when an ongoing source could endanger household members or coworkers. [15][20]

## Prevent recurrent household and occupational exposure

Source control is the definitive prevention strategy.

CDC recommends battery-operated or battery-backup CO detectors near every sleeping area, replacement according to manufacturer instructions or every 5 years, and annual service of heating systems, water heaters, and gas-, oil-, or coal-burning appliances. [15]

Generators should never be used inside a home or garage, even with doors or windows open; place them outdoors more than 20 feet from windows, doors, and vents. Charcoal grills, portable gas camp stoves, and unvented combustion devices should not be used indoors. [15]
- After a suspected household exposure, advise patients not to re-enter the source environment until it has been evaluated and made safe. [15]
- Ask about workplace combustion exposures, including industrial kitchens and fire-related work; occupational CO exposure occurs across diverse industries. [14][20]

## Common questions

### Can a normal pulse oximetry reading exclude carbon monoxide toxicity?

No. Conventional pulse oximetry cannot reliably distinguish carboxyhemoglobin from oxyhemoglobin. Use co-oximetry in a patient with compatible exposure, but begin oxygen treatment based on clinical suspicion. [16][7]

### Should every patient with carbon monoxide toxicity undergo cardiac testing?

The supplied contemporary cardiovascular review recommends initial ECG, troponin I, BNP or NT-proBNP, and transthoracic echocardiography or focused cardiac ultrasound because CO-related myocardial injury can be clinically silent. [7]

### What should trigger coronary angiography in carbon monoxide toxicity?

Urgent coronary angiography is suggested when ST-elevation myocardial infarction on ECG corresponds to a regional wall-motion abnormality on echocardiography. Routine coronary imaging is not recommended solely for CO-related myocardial injury. [7]

### Does a low carboxyhemoglobin level rule out severe toxicity or delayed sequelae?

No. COHb may decline after source removal and oxygen therapy, and risk for delayed neurologic sequelae correlates poorly with COHb. Interpret the value with timing, treatment, exposure history, and end-organ findings. [10]

### When should hyperbaric oxygen be considered?

Hyperbaric oxygen should be discussed urgently with toxicology or a hyperbaric center for significant neurologic, cardiac, or hemodynamic toxicity, but the supplied sources do not support a single universal COHb threshold. [7][9][10]

## References
1. - IIER - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219962Orig1s000Lbl.pdf
2. Application - Product Code Builder — www.accessdata.fda.gov — https://www.accessdata.fda.gov/SCRIPTS/ORA/PCB/index.cfm?action=main.results
3. Device Registration and Listing Module System — www.access.fda.gov — https://www.access.fda.gov/drlm/mainMenu.htm
4. An Update to the American Heart Association Guidelines ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001161
5. Abstract 4145376: Carbon Monoxide-Induced Atrial ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circ.150.suppl_1.4145376
6. A systematic review and meta-analysis: Heliyon — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(24)10093-X
7. Practical Recommendations for the Evaluation and ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jchf.2024.01.001
8. Neural Circulatory Responses to Carbon Monoxide in ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/01.HYP.29.5.1114
9. Cardiovascular Manifestations of Moderate to Severe Carbon Monoxide Poisoning — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2005.01.044
10. Inflammatory responses to acute carbon monoxide poisoning and the role of plasma gelsolin — www.science.org — https://www.science.org/doi/10.1126/sciadv.ado9751
11. Increased Risk of Congestive Heart Failure Following ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.120.007267
12. fact sheet for healthcare providers: emergency use ... — go.nature.com — https://go.nature.com/3zbxvqg
13. Toxicological Profile for Carbon Monoxide — www.atsdr.cdc.gov — https://www.atsdr.cdc.gov/toxprofiles/tp201-p.pdf
14. Fact Sheets and Other Resources | Carbon Monoxide Poisoning | CDC — www.cdc.gov — https://www.cdc.gov/carbon-monoxide/factsheets/index.html
15. Carbon Monoxide Poisoning Basics | Carbon Monoxide Poisoning |... — www.cdc.gov — https://www.cdc.gov/carbon-monoxide/about/index.html
16. Focus on Diagnosis: Co-oximetry | Pediatrics In Review — pedsinreview.aappublications.org — https://pedsinreview.aappublications.org/content/28/2/73
17. OCCUPATIONAL EXPOSURE — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/19324/cdc_19324_DS1.pdf
18. UPCC 24116/IRB#826253 A Phase II Pilot Trial of ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/06/NCT03032406/Prot_000.pdf
19. UNIVERSITY OF PENNSYLVANIA RESEARCH STUDY ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/01/NCT03169101/ICF_001.pdf
20. Unintentional Carbon Monoxide Poisoning From an ... — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/189059/cdc_189059_DS1.pdf
21. Clinical Research Protocol — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/81/NCT04332081/Prot_SAP_000.pdf
22. CDC Clinical Practice Guideline for Prescribing Opioids ... — www.cdc.gov — https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm
23. Incidence of severe unintentional carbon monoxide ... — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/64848
24. Study Details | NCT06374225 | Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT06374225

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.